← All trials
NCT05870839
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- May 23, 2023
- Last posted
- Nov 21, 2023
- Enrollment
- 150
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- University of MarylandOfficial
- University of RochesterOfficial
- Emory UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.